Role of FOXM1 expression inbibition regulated by thiostrepton in the proliferation and apoptosis of lung cancer cells

doi:10.3760/cma.j.issn.1673-422X.2014.02.017

Abstract

Abstract: ObjectiveTo investigate the effect of thiostrepton (TST) on cell proliferation, apoptosis and the chemosensitivity of nonsmall cell cancer (NSCLC) cell lines A549 to AG1478 (EGFRTKI). MethodsNSCLC cell A549 was treated with TST, AG1478 or the combination of the two drugs. CCK8 cell viability assay was performed to determine the relative growth suppression rate of A549 cell. The expression level of forkhead transcription factors M1 (FOXM1) was studied by western blot. Caspase3 colorimetric assay was employed to evaluate the effect of TST on Caspase3 activity. A siRNA targeting FOXM1 was designed and transfected into A549 cells. RTPCR and western blot were used to examine the expressions of FOXM1 and proliferation and apoptosis related molecules. ResultsTST increased the chemosensitivity of A59 cells to AG1478, a kind of moleculartargeted agent to advanced lung cancer, which made the IC50 value reduce from (4.35±0.45) μmol/L to (0.73±0.05) μmol/L (t=11.02, P＜0.05). Besides, TST inhibited the expressions of FOXM1 and its effectors including cMyc, Cyclin B1 and Bcl2, while upregulated P21, Cleaved Caspase3 and Cleaved PARP. Meanwhile, TST improved the activity of Caspase3, which showed time and dosedependent effects. FOXM1 siRNA changes the expression of the downstream effectors such as cMyc, Cyclin B1, Bcl2, P21 and Cleaved PARP, which was similar to the effect of TST. Also, the fluorescent expression of Cleaved Caspase3 significantly increased in A549 cells. ConclusionTST can significantly inhibit proliferation and induce apoptosis by downregulating the expression of FOXM1, and then increase chemosensitivity of A549 cell to AG1478.

Key words: Lung neoplasms, RNA interference, Forkhead transcription factors M1, Thiostrepton, Drug sensitivity

Gong Xiaodi, Yuan Haihua, Wang Jiongyi, Guo Yuehui, Kong Feifei, Jiang Bin. Role of FOXM1 expression inbibition regulated by thiostrepton in the proliferation and apoptosis of lung cancer cells[J]. Journal of International Oncology, 2014, 41(2): 135-140.

References

［1］ Wierstra I, Alves J. FOXM1, a typical proliferationassociated transcription factor［J］. Biol Chem, 2007, 388(12): 1257-1274. ［2］ Xia L, Mo P, Huang W, et al. The TNFα/ROS/HIF1induced upregulation of FoxMⅠ expression promotes HCC proliferation and resistance to apoptosis［J］. Carcinogenesis, 2012, 33(11): 2250-2259. ［3］ Yang C, Chen H, Yu L, et al. Inhibition of FOXM1 transcription factor suppresses cell proliferation and tumor growth of breast cancer［J］. Cancer Gene Ther, 2013, 20(2): 117-124. ［4］ Priller M, Pschl J, Abro L, et al. Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients［J］. Clin Cancer Res, 2011, 17(21): 6791-6801. ［5］ Huang C, Qiu Z, Wang L, et al. A novel FoxM1caveolin signaling pathway promotes pancreatic cancer invasion and metastasis［J］. Cancer Res, 2012, 72(3): 655-665. ［6］ Liu Y, Hock JM, Van Beneden RJ, et al. Aberrant overexpression of FOXM1 transcription factor plays a critical role in lung carcinogenesis induced by low doses of arsenic［J］. Mol Carcinog, 2012, In press. ［7］ Yang DK, Son CH, Lee SK, et al. Forkhead box M1 expression in pulmonary squamous cell carcinoma: correlation with clinicopathologic features and its prognostic significance［J］. Hum Pathol, 2009, 40(4): 464-470. ［8］ Gialmanidis IP, Bravou V, Amanetopoulou SG, et al. Overexpression of hedgehog pathway molecules and FOXM1 in nonsmall cell lung carcinomas［J］. Lung Cancer, 2009, 66(1): 64-74. ［9］ Nilsson I, Hoffmann I. Cell cycle regulation by the Cdc25 phosphatase family［J］. Prog Cell Cycle Res, 2000, 4: 107-114. ［10］ Chen YJ, DominguezBrauer C, Wang Z, et al. A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclinCDK1［J］. J Biol Chem, 2009, 284(44): 30695-30707. ［11］ Bellelli R, Castellone MD, GarciaRostan G, et al. FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma［J］. Endocr Relat Cancer, 2012, 19(5): 695-710. ［12］ Ackermann Misfeldt A, Costa RH, Gannon M. Betacell proliferation, but not neogenesis, following 60% partial pancreatectomy is impaired in the absence of FoxM1［J］. Diabetes, 2008, 57(11): 3069-3077. ［13］ Petrovic V, Costa RH, Lau LF, et al. FoxM1 regulates growth factorinduced expression of kinaseinteracting stathmin (KIS) to promote cell cycle progression［J］. J Biol Chem, 2008, 283(1): 453-460. ［14］ Bhat UG, Halasi M, Gartel AL. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells［J］. PLoS One, 2009, 4(5): e5592. ［15］ Jonker HR, Ilin S, Grimm SK, et al. L11 domain rearrangement upon binding to RNA and thiostrepton studied by NMR spectroscopy［J］. Nucleic Acids Res, 2007, 35(2): 441-454. ［16］ Kwok JM, Myatt SS, Marson CM, et al. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression［J］. Mol Cancer Ther, 2008, 7(7): 2022-2032. ［17］ Kwok JM, Peck B, Monteiro LJ, et al. FOXM1 confers acquired cisplatin resistance in breast cancer cell［J］. Mol Cancer Res, 2010, 8(1): 24-34. ［18］ Krol J, Francis RE, Albergaria A, et al. The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells［J］. Mol Cancer Ther, 2007, 6(12 Pt 1): 3169-3179. ［19］ Hui RC, Francis RE, Guest SK, et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells［J］. Mol Cancer Ther, 2008, 7(3): 670-678. ［20］ McGovern UB, Francis RE, Peck B, et al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer［J］. Mol Cancer Ther, 2009, 8(3): 582-591.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36.
[3]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng. Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection [J]. Journal of International Oncology, 2023, 50(12): 711-716.
[4]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin. Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging [J]. Journal of International Oncology, 2023, 50(11): 655-660.
[5]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun. Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model [J]. Journal of International Oncology, 2022, 49(9): 532-536.
[6]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying. Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses [J]. Journal of International Oncology, 2022, 49(8): 459-463.
[7]	Cai Gangxiang, Li Jing, Xu Bin. Advances in neoadjuvant immunotherapy for lung cancer [J]. Journal of International Oncology, 2022, 49(6): 366-370.
[8]	Zhang Jingxian, Yi Dan, Li Xiaojiang. Application of antibody-drug conjugates in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(5): 296-301.
[9]	Gao Min, Feng Jing, Wang Li, Zhong Hai, Wen Yuting, Wan Bing, Zhang Xiuwei. Application of microbiota in the early diagnosis and adjunctive treatment of lung cancer [J]. Journal of International Oncology, 2022, 49(4): 247-251.
[10]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu. Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(3): 140-145.
[11]	Xie Hongxia, Zuo Jinhui, Liao Dongying, Deng Renfen, Yao Yang, Jia Yingjie, Li Xiaojiang, Kong Fanming. Application of PD-L1 inhibitors in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(2): 111-115.
[12]	Huang Huayu, Song Qibin, Gong Hongyun, Song Jia. Analysis on the incidence and risk factors of pneumonia in patients with lung cancer receiving thoracic radiotherapy and immunotherapy [J]. Journal of International Oncology, 2022, 49(12): 718-723.
[13]	Zhang Hongjiao, Jiang Jie, Huang Wei. Research progress of functional imaging-assisted radiotherapy target delineation of lung cancer with atelectasis [J]. Journal of International Oncology, 2022, 49(1): 51-55.
[14]	Hu Ge, Su Jie, Li Qiangwei, Xu Peng, Xu Xiuli, Qian Xiaotao. Value of CD4/CD8 ratio and total B lymphocytes before radiotherapy in predicting radiation pneumonitis in patients with esophageal cancer and lung cancer [J]. Journal of International Oncology, 2021, 48(9): 523-526.
[15]	Wang Jun, Zhao Xia, Li Haifei, Zhang Cheng. Clinic diagnostic value of MSCT imaging features in nodular lung adenocarcinoma subtype [J]. Journal of International Oncology, 2021, 48(9): 537-543.